Atossa Therapeutics Inc ATOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
Stocks to Watch: Atossa Therapeutics, Union Pacific
Trading Information
- Previous Close Price
- $1.94
- Day Range
- $1.85–2.00
- 52-Week Range
- $1.70–14.85
- Bid/Ask
- $1.88 / $2.40
- Shares Outstanding
- 9.98M
- Market Cap
- $19.56M
- Volume/Avg
- 56,354 / 71,524
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
Valuation
Metric | ATOS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.90 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ATOS |
|---|---|
Quick Ratio | 4.37 |
Current Ratio | 5.35 |
Interest Coverage | — |
Quick Ratio
ATOS
Profitability
Metric | ATOS |
|---|---|
Return on Assets (Normalized) | −79.26% |
Return on Equity (Normalized) | −95.33% |
Return on Invested Capital (Normalized) | −98.86% |
Return on Assets
ATOS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|VlJg!^F | LOCK|%%Kn | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|C^Ws&Vx | LOCK|YngBd | $99B | |||
| Moderna Inc MRNA | LOCK|%^%s?VW | LOCK|t$J | $90B | |||
| argenx SE ADR ARGX | LOCK|&$^@Pf | LOCK|X#% | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|<<P!?!x | LOCK|@& | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|qng!b&j | LOCK|!R>H | $31B | |||
| Incyte Corp INCY | LOCK|WLC#PM& | LOCK|P!G | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|q?vNx! | LOCK|%$$p | $22B | |||
| BioNTech SE ADR BNTX | LOCK|g$?>CV | LOCK|lL | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|SWhS!# | LOCK|bD | $16B |
United States